Synonyms: compound C9 [WO2020081879A2] | PTC-857 | PTC857
Compound class:
Synthetic organic
Comment: Utreloxastat (PTC-857) is described as a 15-lipoxygenase inhibitor in its INN record. It was developed for potential to treat α-synucleinopathies, tauopathies, ALS and other brain injuries/insults [1].
|
|
References |
1. Hinman AW, Holst CR, Minella A, Mollard P, Pintchovski S, Trimmer JK, Torrey E. (2020)
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS. Patent number: WO2020081879A2. Assignee: Ptc Therapeutics, Inc.. Priority date: 17/10/2019. Publication date: 23/04/2020. |